BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/13/2026 9:40:25 AM | Browse: 2 | Download: 1
 |
Received |
|
2026-01-05 08:37 |
|
Peer-Review Started |
|
2026-01-05 08:38 |
|
First Decision by Editorial Office Director |
|
2026-01-20 10:26 |
|
Return for Revision |
|
2026-01-20 11:11 |
|
Revised |
|
2026-02-04 06:29 |
|
Publication Fee Transferred |
|
2026-02-05 10:21 |
|
Second Decision by Editor |
|
2026-03-25 02:38 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-25 04:29 |
|
Articles in Press |
|
2026-03-25 04:29 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-17 07:19 |
|
Publish the Manuscript Online |
|
2026-07-13 09:40 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Lenvatinib and pembrolizumab plus FOLFOX-hepatic arterial infusion chemotherapy in locally advanced, potentially resectable hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xi Chen, Hao Liao, Jie Chen, Lin-hui Peng, Ji-Hao Zhang, Xiu-Xiu Xuyun, Ya-Jin Chen and Tao Chen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Guangdong Basic and Applied Basic Research Foundation Project |
No. 2024A1515220164 |
|
| Corresponding Author |
Tao Chen, PhD, Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, No. 107 Yanjiang West Road, Yuexiu District, Guangzhou 510120, Guangdong Province, China. ct0498@126.com |
| Key Words |
Hepatocellular carcinoma; Conversion therapy; Transhepatic arterial perfusion chemotherapy; Lenvatinib; Pembrolizumab |
| Core Tip |
This retrospective study of 38 patients with initially unresectable hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy, lenvatinib and pembrolizumab showed promising results. The overall response rate was 50.0%-52.6% with a disease control rate of 97.4%. The conversion to surgery rate was 44.7%, with a pathological complete response rate of 7.9%. Treatment was well-tolerated, with only 10.5% experiencing grade III/IV adverse events. Patients achieving successful conversion had significantly better long-term survival. |
| Publish Date |
2026-07-13 09:40 |
| Citation |
Chen X, Liao H, Chen J, Peng LH, Zhang JH, Xuyun XX, Chen YJ, Chen T. Lenvatinib and pembrolizumab plus FOLFOX-hepatic arterial infusion chemotherapy in locally advanced, potentially resectable hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(7): 118522
|
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i7/118522.htm |
| DOI |
https://doi.org/10.4251/wjgo.v18.i7.118522 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
